Clinical trialNCT06017258RecruitingPhase 1Interventional

A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

SponsorMemorial Sloan Kettering Cancer CenterEnrollment15Acute Myeloid LeukemiaAcute Myeloid Leukemia RefractoryAcute Myeloid Leukemia, in RelapseRefractory Acute Myeloid LeukemiaRelapsed Acute Myeloid Leukemia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to find out whether CD371-YSNVZ-IL18 CAR T cells are safe, and to look for the highest dose of CD371-YSNVZ-IL18 CAR T cells that cause few or mild side effects in participants.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Mark Geyer, MD
Memorial Sloan Kettering Cancer Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Memorial Sloan Kettering at Basking Ridge (limited Protocol Activities)
Basking Ridge, New Jersey, United States
Recruiting
Memorial Sloan Kettering Monmouth (limited Protocol Activities)
Middletown, New Jersey, United States
Recruiting
Memorial Sloan Kettering Bergen (limited Protocol Activities)
Montvale, New Jersey, United States
Recruiting
Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (limited Protocol Activities)
Commack, New York, United States
Recruiting
Memorial Sloan Kettering Westchester (limited Protocol Activities)
Harrison, New York, United States
Recruiting
Memorial Sloan Kettering Cancer Center (all Protocol Activites)
New York, New York, United States
Recruiting
Memorial Sloan Kettering Nassau (limited Protocol Activites)
Rockville Centre, New York, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CD371-specific/YSNVz/I-18 CAR T cells

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 1 Sept 2023
Primary completion: 17 Dec 2026
Completion: 17 Dec 2026
Last update posted: 22 Jun 2026
Registered enrollment: 15
Registry id: NCT06017258

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.